SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
liv12439-sup-0001-FigS1.epsimage/eps891KFig. S1. Selection of patients for this analysis. Reasons for premature withdrawal are shown for patients included in the analysis.
liv12439-sup-0002-FigS2.epsimage/eps860KFig. S2. Positive predictive value (95% confidence interval) of DTRP score for SVR.
liv12439-sup-0004-FigS3.epsimage/eps908KFig. S3. SVR rates in patients with a DTRP score of 0–2, 3–4 and ≥5 points according to the extent of hepatic fibrosis at baseline. Only patients who had previously undergone an invasive or non-invasive fibrosis assessment were included.
liv12439-sup-0004-FigS4.epsimage/eps788KFig. S4. SVR rates in patients with a DTRP score of 0–2, 3–4 and ≥5 points according to host IL28B genotype in a subset of patients in validation dataset 2, which contains data from treatment-naive genotype 1 mono-infected Austrian patients who received response-guided therapy for 24, 48 or 72 weeks with standard doses of peginterferon alfa-2a (40kD)/ribavirin.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.